On June 13th, Gelonhui reported that an investor asked Hainan Shuangcheng Pharmaceuticals (002693.SZ) on the investor interaction platform, "Has the Acetate Ornipressin Injection ANDA obtained FDA approval and been sold in the US market?" The company responded that its product, Acetate Ornipressin Injection, has not yet been launched for sale in the US market.
双成药业(002693.SZ)：产品醋酸奥曲肽注射液美国市场目前还未上市销售
Hainan Shuangcheng Pharmaceuticals (002693.SZ): At present, the product Acotiamide Acetate Injection has not yet been launched for sale in the USA market.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.